The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Key trials that will affect the therapy landscape for NSCLC
Speaking at the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Benjamin Besse, MD, PhD from the Institute Gustave Roussy, Villejuif, France discusses the implications of the recent MK-3475-189/KEYNOTE-189 (NCT02578680) trial on front-line therapy for the treatment of non-small cell lung cancer (NSCLC). Dr Besse outlines the key questions surrounding the results, concerning what therapies will be used on the front-line for NSCLC and in which subsets of patients. The results of the Phase III MYSTIC (NCT02453282) and NEPTUNE (NCT02542293) trials both investigating the combination of durvalumab with tremelimumab, and the CheckMate-227 (NCT02477826) trial looking at ipilimumab combined with nivolumab will also prove pivotal in determining the future therapeutic landscape for NSCLC.
